Semliki Forest virus vectors expressing transforming growth factor beta inhibit experimental autoimmune encephalomyelitis in Balb/c mice

Biochemical and Biophysical Research Communications

Volumn 355, Issue 3, 2007, Pages 776-781

  Vähä Koskela, Markus J V ^a,b   Kuusinen, Tiina I ^a,b   Holmlund Hampf, Jeanette C ^a   Furu, Petra T ^a   Heikkilä, Jari E ^a   Hinkkanen, Ari E ^a  

^a ÅBO AKADEMI UNIVERSITY   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Central nervous system (CNS); Experimental autoimmune encephalomyelitis (EAE); Gene therapy; Semliki Forest virus (SFV); Transforming growth factor beta 1 (TGF 1)

Indexed keywords

LUCIFERASE; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1; VIRUS VECTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INHIBITION; ENZYME SYNTHESIS; FEMALE; IMMUNOMODULATION; IN SITU HYBRIDIZATION; MINK; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEMLIKI FOREST ALPHAVIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS EXPRESSION;

ANIMALS; BRAIN; BRAIN CHEMISTRY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE THERAPY; GENETIC VECTORS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; SEMLIKI FOREST VIRUS; TRANSFORMING GROWTH FACTOR BETA1;

MUS; MUSTELA; SEMLIKI FOREST VIRUS;

EID: 33847265305     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.02.026     Document Type: Article

References (23)

1. Gold R., Linington C., and Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129 (2006) 1953-1971
2. Baker D., and Hankey D.J. Gene therapy in autoimmune, demyelinating disease of the central nervous system. Gene Ther. 10 (2003) 844-853
3. Wahl S.M. Transforming growth factor beta: the good, the bad, and the ugly. J. Exp. Med. 180 (1994) 1587-1590
4. Govinden R., and Bhoola K.D. Genealogy, expression, and cellular function of transforming growth factor-beta. Pharmacol. Ther. 98 (2003) 257-265
5. Gorelik L., Constant S., and Flavell R.A. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J. Exp. Med. 195 (2002) 1499-1505
6. Thorbecke G.J., Umetsu D.T., deKruyff R.H., Hansen G., Chen L.Z., and Hochwald G.M. When engineered to produce latent TGF-beta1, antigen specific T cells down regulate Th1 cell-mediated autoimmune and Th2 cell-mediated allergic inflammatory processes. Cytokine Growth Factor Rev. 11 (2000) 89-96
7. Johns L.D., Flanders K.C., Ranges G.E., and Sriram S. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1. J. Immunol. 147 (1991) 1792-1796
8. Piccirillo C.A., and Prud'homme G.J. Prevention of experimental allergic encephalomyelitis by intramuscular gene transfer with cytokine-encoding plasmid vectors. Hum. Gene Ther. 10 (1999) 1915-1922
9. Prud'homme G.J., and Piccirillo C.A. The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases. J. Autoimmun. 14 (2000) 23-42
10. Racke M.K., Dhib-Jalbut S., Cannella B., Albert P.S., Raine C.S., and McFarlin D.E. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J. Immunol. 146 (1991) 3012-3017
11. Santambrogio L., Hochwald G.M., Saxena B., Leu C.H., Martz J.E., Carlino J.A., Ruddle N.H., Palladino M.A., Gold L.I., and Thorbecke G.J. Studies on the mechanisms by which transforming growth factor-beta (TGF-β) protects against allergic encephalomyelitis. Antagonism between TGF-β and tumor necrosis factor. J. Immunol. 151 (1993) 1116-1127
12. Boche D., Cunningham C., Gauldie J., and Perry V.H. Transforming growth factor-beta 1-mediated neuroprotection against excitotoxic injury in vivo. J. Cereb. Blood Flow Metab. 23 (2003) 1174-1182
13. Zhu Y., Yang G.Y., Ahlemeyer B., Pang L., Che X.M., Culmsee C., Klumpp S., and Krieglstein J. Transforming growth factor-beta 1 increases bad phosphorylation and protects neurons against damage. J. Neurosci. 22 (2002) 3898-3909
14. Diemel L.T., Jackson S.J., Cuzner M.L., and TGF-beta1 R.f. FGF-2 and PDGF-AA in a myelination of CNS aggregate cultures enriched with macrophages. J. Neurosci. Res. 74 (2003) 858-867
15. Calabresi P.A., Fields N.S., Maloni H.W., Hanham A., Carlino J., Moore J., Levin M.C., Dhib-Jalbut S., Tranquill L.R., Austin H., McFarland H.F., and Racke M.K. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology 51 (1998) 289-292
16. Vähä-Koskela M.J., Tuittila M.T., Nygårdas P.T., Nyman J.K., Ehrengruber M.U., Renggli M., and Hinkkanen A.E. A novel neurotropic expression vector based on the avirulent A7(74) strain of Semliki Forest virus. J. Neurovirol. 9 (2003) 1-15
17. Nygårdas P.T., Grönberg S.A., Heikkilä J., Joronen K., Sorsa T., and Hinkkanen A.E. Treatment of experimental autoimmune encephalomyelitis with a neurotropic alphavirus vector expressing tissue inhibitor of metalloproteinase-2. Scand. J. Immunol. 60 (2004) 372-381
18. Vähä-Koskela M.J., Kallio J.P., Jansson L.C., Heikkilä J.E., Zakhartchenko V.A., Kallajoki M.A., Kähäri V.M., and Hinkkanen A.E. Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res. 66 (2006) 7185-7194
19. Fleming K.K., Bovaird J.A., Mosier M.C., Emerson M.R., LeVine S.M., and Marquis J.G. Statistical analysis of data from studies on experimental autoimmune encephalomyelitis. J. Neuroimmunol. 170 (2005) 71-84
20. Brunner A.M., Marquardt H., Malacko A.R., Lioubin M.N., and Purchio A.F. Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins. J. Biol. Chem. 264 (1989) 13660-13664
21. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., Hatton R.D., Wahl S.M., Schoeb T.R., and Weaver C.T. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441 (2006) 231-234
22. Jerusalmi A., Morris-Downes M.M., Sheahan B.J., and Atkins G.J. Effect of intranasal administration of Semliki Forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis. Mol. Ther. 8 (2003) 886-894
23. Graham A., Walker R., Baird P., Hahn C.N., and Fazakerley J.K. CNS gene therapy applications of the Semliki Forest virus 1 vector are limited by neurotoxicity. Mol. Ther. 13 (2006) 631-635